Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib with Chemoradiation for Esophageal Cancer
NCT00393068Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in esophageal cancer, sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response Rate at 18 months. Started Feb 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00393068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393068.